{{DISPLAYTITLE:''N''-Desalkylflurazepam}}
{{Drugbox
| IUPAC_name = 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
| image =Desalkylflurazepam.svg
| width = 222
| alt = 
| image2 = Desalkylflurazepam ball-and-stick model.png
| width2 = 
| drug_name =

<!--Clinical data-->
| tradename = 
| licence_EU = <!-- EMA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| DailyMedID = <!-- preference to licence_US -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = Schedule IV
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| dependency_liability = 
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =
<!--Identifiers-->
| CAS_number = 2886-65-9
| CAS_supplemental = 
| ATCvet = 
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix = 
| ATC_supplemental = 
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| PubChem = 4540
| ChemSpiderID = 4381 
| ChEMBL = 974
| synonyms =
<!--Chemical data-->
| C=15 | H=10 | Cl=1 | F=1 | N=2 | O=1
| molecular_weight = 288.70 g/mol
| SMILES = Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23 
| density = 
| melting_point = 205
| melting_high = 206
| melting_notes = <ref>[[SciFinder]] record for CAS#2886-65-9</ref>
| boiling_point = 
| boiling_notes = 
| solubility = 
| specific_rotation = 
| sec_combustion = 
}}

'''''N''-Desalkylflurazepam''' (also known as '''Norflurazepam''') is a [[benzodiazepine]] analog and an [[active metabolite]] of several other [[benzodiazepine]] drugs including [[flurazepam]],<ref name=":0">{{cite journal | doi = 10.1016/S0378-4347(00)84153-5| title = Rapid quantitation of flurazepam and its major metabolite, N-desalkylflurazepam, in human plasma by gas—liquid chromatography with electron-capture detection| journal = Journal of Chromatography B| volume = 222| issue = 3| pages = 491–495| year = 1981| last1 = Riva| first1 = Roberto| last2 = De Anna| first2 = Marco| last3 = Albani| first3 = Fiorenzo| last4 = Baruzzi| first4 = Agostino}}</ref> [[flutoprazepam]],<ref>{{Cite journal | pmid= 2633923| year= 1989| author1= Barzaghi| first1= N| title= Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects| journal= European journal of drug metabolism and pharmacokinetics| volume= 14| issue= 4| pages= 293–8| last2= Leone| first2= L| last3= Monteleone| first3= M| last4= Tomasini| first4= G| last5= Perucca| first5= E| doi=10.1007/bf03190114}}</ref> [[fludiazepam]],<ref>{{Cite book | title = Human Toxicology | editor = J. Descotes | date = 1996 | page = 43}}</ref> [[midazolam]],<ref>{{Cite journal | doi = 10.1002/dta.1484| pmid = 23713025| title = Desalkylflurazepam found in patients' samples after high-dose midazolam treatment| journal = Drug Testing and Analysis| volume = 5| issue = 9–10| pages = 745–7| year = 2013| last1 = Vogt| first1 = Susanne| last2 = Kempf| first2 = Jürgen| last3 = Buttler| first3 = Jürgen| last4 = Auwärter| first4 = Volker| last5 = Weinmann| first5 = Wolfgang}}</ref> [[quazepam]],<ref name=Nikaido >{{cite journal | last1 = Nikaido | first1 = AM | last2 = Ellinwood Jr | first2 = EH | title = Comparison of the effects of quazepam and triazolam on cognitive-neuromotor performance | journal = Psychopharmacology | volume = 92 | issue = 4 | pages = 459–64 | year = 1987 | pmid = 2888152 | doi=10.1007/bf00176478}}</ref> and [[ethyl loflazepate]].<ref>{{cite journal | journal = Annals of Biomedical Engineering | date = 1989 |volume = 17 |issue =6 | pages =633–646 | title = Pharmacokinetic modeling of ethyl loflazepate (VictanR) and its main active metabolites | author = B. B. Ba, A. Iliadis, J. P. Cano| pmid = 2574017 | last2 = Iliadis | last3 = Cano | doi=10.1007/bf02367467}}</ref><ref>{{cite journal | doi = 10.1016/S0378-4347(00)84498-9| title = Determination of circulating ethyl loflazepate metabolites in the baboon by radio-high-performance liquid chromatography with injection of crude plasma samples: Comparison with solvent extraction and thin-layer chromatography| journal = Journal of Chromatography B| volume = 342| pages = 159–165| year = 1985| last1 = Davi| first1 = H.| last2 = Guyonnet| first2 = J.| last3 = Necciari| first3 = J.| last4 = Cautreels| first4 = W.}}</ref>  It is long-acting, prone to accumulation, and binds unselectively to the various [[benzodiazepine receptor]] subtypes.<ref name=Nikaido/>  It has been sold as a designer drug from 2016 onward.

==Synonyms==
* ''N''-1-Desalkyl[[flurazepam]]
* ''N''-Desalkyl-[[2-oxoquazepam]]
* ''N''-Desalkyl[[flunitrazepam]]
* ''N''-Desalkyl[[flutoprazepam]]
* 7-Chloro[[flubromazepam]]
* Dealkylflurazepam
* Desalkylflurazepam
* Descarbethoxy[[loflazepate]]
* Nor[[fludiazepam]]
* Norflurazepam
* Norflutoprazepam
* Ro 5-3367
* TL8002277

==References==
{{reflist}}

{{Benzodiazepines}}
{{GABAAR PAMs}}

{{DEFAULTSORT:Desalkylflurazepam, N-}}
[[Category:Benzodiazepines]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Human drug metabolites]]


{{sedative-stub}}